{"ticker": {"uuid": "ef9f0c6b-49bc-419d-bfe6-5ff2b1d4ec6d", "symbol": "KYNB", "name": "Kyntra Bio, Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Kyntra Bio Inc. (KYNB) Sheds 1.5% as Shares Test Key Support Zone - Counter Trend Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPYm5XZ3ZpbUMya2RBVFVHdnJCWlRaaXpSZUxQaTVUdGRKbTZ6WWh1RVlNbVV6a1BPQjVid052OUZSZDFVMFZqZlhzcU93OTZhcHZSdVA4Vi14Qm9PN1hTWEtwbGJzbDBvTWZWZURuQTllTUh2UTJQV3g2UFZXMmd5TmZ3RTMybGpvaHNNM2FnbkYtUFdyMm9RWWhfWlN1b1FITUVpN0RyWQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-16T00:36:24+00:00", "published_display": "16 Jul 2026 00:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "If You Invested $1,000 in KYNTRA BIO INC (KYNB)", "summary": "This article analyzes the hypothetical returns of investing $1,000 in KYNTRA BIO INC (KYNB). It reveals that an investment made a year ago would currently be worth $788, representing a 21% decrease. The article also provides an overview of Kyntra Bio, Inc.'s business, focusing on", "url": "https://www.stocktitan.net/tools/stock-return-calculator/KYNB", "source_name": "Stock Titan", "published_at": "2026-07-09T01:41:00", "published_display": "09 Jul 2026 01:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Initiates Kyntra Bio(KYNB.US) With Buy Rating, Announces Target Price $35", "summary": "Oppenheimer has initiated coverage on Kyntra Bio (KYNB.US) with a \"Buy\" rating. The firm also announced a target price of $35 for the company's shares. This indicates a positive outlook from Oppenheimer on Kyntra Bio's future performance.", "url": "https://www.moomoo.com/t/news/post/72539511/yNeMIv6Ynb?futusource=nnq_personal_guest", "source_name": "Moomoo", "published_at": "2026-07-08T05:41:00", "published_display": "08 Jul 2026 05:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Maintains Kyntra Bio(KYNB.US) With Buy Rating, Maintains Target Price $35", "summary": "Oppenheimer has reiterated its Buy rating for Kyntra Bio (KYNB.US), maintaining a target price of $35. This indicates continued confidence from the firm in the biotechnology company's performance and future prospects.", "url": "https://www.moomoo.com/news/post/72586860/oppenheimer-maintains-kyntra-bio-kynbus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-07-07T21:10:59", "published_display": "07 Jul 2026 21:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer initiates Kyntra Bio stock coverage with outperform rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQV0VfQjZVbVRrdTJyYm1FbDRPWFFpbFktTGxYb2hnanowMW1zS1o1N0QwY24yNXdkREZLWG5zR3FHOXVTbV85MHM0UWpsSXNfcDZJSHZSRE5Xa2NEeS1LSk92cm9VNFlFbTFxOVNyell3bENmSm95UktjRlZFeVozOUlHS1ktM2dqZE05dW02TDl4cTBaUkM0ZXlLbjI2UHBtalpTYl9zV2piejJ3aU1MM04yZ0kwZk5UNlFia3VUSDdMVk5FZVhNN2xn?oc=5", "source_name": "Investing.com", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Net margin % of Kyntra Bio, Inc. \u2013 DUS:1FG0", "summary": "This article provides access to the net margin percentage for Kyntra Bio, Inc. (DUS:1FG0) on the TradingView platform. It is a financial data point for the company listed on the Dusseldorf Stock Exchange. The content primarily focuses on the display of this financial metric withi", "url": "https://www.tradingview.com/symbols/DUS-1FG0/financials-statistics-and-ratios/net-margin/", "source_name": "TradingView", "published_at": "2026-07-05T08:41:36", "published_display": "05 Jul 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Kyntra Bio, Inc. \u2013 DUS:1FG0", "summary": "This article provides the forward price-to-sales ratio for Kyntra Bio, Inc. (DUS:1FG0) on the Dusseldorf Stock Exchange. It indicates no current trading data and emphasizes that the content focuses on financial metrics for this specific pharmaceutical stock.", "url": "https://www.tradingview.com/symbols/DUS-1FG0/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T17:39:50", "published_display": "03 Jul 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Kyntra Bio, Inc. \u2013 DUS:1FG0", "summary": "The article presents the enterprise value to revenue forward for Kyntra Bio, Inc. (DUS:1FG0) on the Dusseldorf Stock Exchange. It indicates that the market was closed with no trades recorded for the period. The content is primarily a financial snapshot on TradingView, noting the ", "url": "https://www.tradingview.com/symbols/DUS-1FG0/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T23:41:26", "published_display": "29 Jun 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Kyntra Bio, Inc. \u2013 NASDAQ:KYNB", "summary": "This article provides access to the \"Price to book forward\" financial data for Kyntra Bio, Inc. (NASDAQ: KYNB) on the TradingView platform. It highlights that the market is currently closed and no trades have occurred for the stock. The content primarily focuses on navigation and", "url": "https://www.tradingview.com/symbols/NASDAQ-KYNB/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T14:11:10", "published_display": "26 Jun 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KYNB Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Kyntra Bio, Inc. (KYNB) stock for 2027, based on analyst ratings. It details the company's current stock price, historical performance, volatility, market capitalization, and upcoming earnings report. The piece also includes f", "url": "https://www.tradingview.com/symbols/NASDAQ-KYNB/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T12:38:58", "published_display": "26 Jun 2026 12:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio, Inc. Actuals & Estimates (NASDAQ:KYNB)", "summary": "Kyntra Bio, Inc. (NASDAQ:KYNB) stock is currently trading at $7.24, showing a 1.73% increase in the past 24 hours. Analysts' future price estimates range from $30.00 to $43.00. The company's last reported earnings were -$3.76 per share, missing the estimate, with revenue at $3.70", "url": "https://www.tradingview.com/symbols/NASDAQ-KYNB/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:11:10", "published_display": "26 Jun 2026 07:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Kyntra Bio, Inc. \u2013 NASDAQ:KYNB", "summary": "The article focuses on the enterprise value to EBIT forward of Kyntra Bio, Inc. (NASDAQ: KYNB). It provides a snapshot of the company's financial overview within the TradingView platform, detailing market data and analytical tools available for investors. The content appears to b", "url": "https://www.tradingview.com/symbols/NASDAQ-KYNB/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T04:10:21", "published_display": "26 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Kyntra Bio, Inc. \u2013 TRADEGATE:1FG0", "summary": "This article provides the \"Price to book forward\" for Kyntra Bio, Inc. (TRADEGATE:1FG0) and indicates that the market is currently closed with no trades. It is a financial data point presented on the TradingView platform.", "url": "https://www.tradingview.com/symbols/TRADEGATE-1FG0/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T02:10:21", "published_display": "26 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio Inc. (KYNB) Edges Higher on Above-Average Volume, Tests Key Resistance Zone - ETH Profile", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOWEpNampFU1AtclpaRWJLWVBNQ0FsZEZoZEwzc05SZEVIZzgwdkJmN1V4YUpqcmtnZnNTY0RzUWVIYUdZaUJWTlF6ZHRPRXdib0hqZHRyWG9YWk9HQlJScFpTU1dFWG1aZHlKQUtRRzRsNW5YdG5uNVNPcmNVZ0FkRk8xQTVCUlp1RU5VUVpzb1BncGlKUkJyaHZlQk4yYWRCX0dZVzV3akJ0ZzUtblBsTkJpc3VUOUpvdERQRQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: EPS Miss Reflects Continued R&D Investment - CEO Earnings Statement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNZmM3WnJSeU9fOTRLQmRHRjJrYV9YREZXRUgwOXBvbVA2QVhONzRUV19QVklIT3dwOUxNNFltWDEyeXpCYUZJQWNYV1JoMU1zS0RjNHBiVmRRQ05wYWFVTnJha3BQd1lfNXVSRlg1cUlxOGxiaFp5aVBLV2t1R2xvSVI2SHdxYi1MdkNNN21BR0VId2JaTVRVUkZMWUt5NDc1Q25VejZEUTNBdlVod1AxQkpTZnBTRHo4Wk96d21VSXc?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Net debt of Kyntra Bio, Inc. \u2013 DUS:1FG0", "summary": "The article focuses on the net debt of Kyntra Bio, Inc. (DUS:1FG0), traded on the Dusseldorf Stock Exchange. It indicates that the market is currently closed with no trades recorded. The content seems to be a financial data page from TradingView, providing an overview of Kyntra B", "url": "https://www.tradingview.com/symbols/DUS-1FG0/financials-balance-sheet/net-debt/", "source_name": "TradingView", "published_at": "2026-06-19T10:40:56", "published_display": "19 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KYNTRA BIO (KYNB) director Ho Maykin awarded 7,000 stock options at $7.13", "summary": "KYNTRA BIO (KYNB) director Ho Maykin was granted 7,000 stock options, which allows him to purchase common stock at an exercise price of $7.13 per share. These options are part of a compensation award and will vest in four equal quarterly installments from the grant date, expiring", "url": "https://www.stocktitan.net/sec-filings/KYNB/form-4-kyntra-bio-inc-insider-trading-activity-1a6eb7da391e.html", "source_name": "Stock Titan", "published_at": "2026-06-19T03:10:13", "published_display": "19 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings ratio of Kyntra Bio, Inc. \u2013 DUS:1FG0", "summary": "This article displays the price to earnings ratio for Kyntra Bio, Inc. (DUS:1FG0) on the TradingView platform. The content is primarily a data point regarding the company's financials on the Dusseldorf Stock Exchange, indicating \"No trades\" at the time of viewing.", "url": "https://www.tradingview.com/symbols/DUS-1FG0/financials-statistics-and-ratios/price-earnings/", "source_name": "TradingView", "published_at": "2026-06-18T21:40:56", "published_display": "18 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio, Inc. Statistics \u2013 DUS:1FG0", "summary": "This page provides detailed financial statistics and ratios for Kyntra Bio, Inc. (DUS:1FG0) listed on the Dusseldorf Stock Exchange. Users can find annual and quarterly data for various metrics, including valuation, profitability, liquidity, solvency ratios, and per-share metrics", "url": "https://www.tradingview.com/symbols/DUS-1FG0/financials-statistics-and-ratios/", "source_name": "TradingView", "published_at": "2026-06-18T19:09:08", "published_display": "18 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Basic earnings per share (basic EPS) of Kyntra Bio, Inc. \u2013 DUS:1FG0", "summary": "This article presents the basic earnings per share (basic EPS) for Kyntra Bio, Inc., traded under the symbol DUS:1FG0 on the Dusseldorf Stock Exchange. It includes period values, changes, and change percentages for this financial metric. The data is provided by ICE Data Services ", "url": "https://www.tradingview.com/symbols/DUS-1FG0/financials-income-statement/earnings-per-share-basic/", "source_name": "TradingView", "published_at": "2026-06-18T18:09:08", "published_display": "18 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio (KYNB) director receives 7,000 options at $7.13 strike", "summary": "Kyntra Bio director Jeffrey L. Edwards was granted 7,000 stock options with an exercise price of $7.13 per share. These options serve as compensation, vesting in four equal quarterly installments, and expire on June 11, 2036. This grant aligns Edwards' equity incentives with the ", "url": "https://www.stocktitan.net/sec-filings/KYNB/form-4-kyntra-bio-inc-insider-trading-activity-5aabfba2d1f7.html", "source_name": "Stock Titan", "published_at": "2026-06-17T23:40:46", "published_display": "17 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio (KYNB) awards 7,000 stock options to director", "summary": "Kyntra Bio Inc. (KYNB) has awarded its director, James A. Schoeneck, 7,000 stock options with an exercise price of $7.13 per share and an expiration date of June 11, 2036. The options will vest in four equal quarterly installments commencing from the grant date of June 12, 2026. ", "url": "https://www.stocktitan.net/sec-filings/KYNB/form-4-kyntra-bio-inc-insider-trading-activity-3ff354a01d74.html", "source_name": "Stock Titan", "published_at": "2026-06-17T23:40:46", "published_display": "17 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KYNTRA BIO (KYNB) director awarded 7,000 stock options at $7.13 strike", "summary": "KYNTRA BIO director Michael Kauffman was granted 7,000 stock options with an exercise price of $7.13 per share and an expiration date of June 11, 2036. The options will vest in four equal quarterly installments from the grant date. This transaction, reported via a Form 4 SEC fili", "url": "https://www.stocktitan.net/sec-filings/KYNB/form-4-kyntra-bio-inc-insider-trading-activity-12e0c1250fa2.html", "source_name": "Stock Titan", "published_at": "2026-06-17T23:40:46", "published_display": "17 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio shareholders elect director and approve executive pay at annual meeting", "summary": "At its 2026 annual meeting, Kyntra Bio shareholders elected Michael Kauffman, M.D., Ph.D., as a Class III director and approved the compensation for the company's named executive officers on an advisory basis. They also ratified PricewaterhouseCoopers LLP as the independent regis", "url": "https://www.investing.com/news/sec-filings/kyntra-bio-shareholders-elect-director-and-approve-executive-pay-at-annual-meeting-93CH-4744179", "source_name": "Investing.com", "published_at": "2026-06-17T09:10:30", "published_display": "17 Jun 2026 09:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio (NASDAQ: KYNB) investors back board, pay and PwC auditor", "summary": "Kyntra Bio (NASDAQ: KYNB) shareholders approved key proposals at their 2026 annual meeting, including the election of Michael Kauffman as a Class III director, advisory approval of executive compensation, and the ratification of PricewaterhouseCoopers LLP as the independent regis", "url": "https://www.stocktitan.net/sec-filings/KYNB/8-k-kyntra-bio-inc-reports-material-event-958a04699a80.html", "source_name": "Stock Titan", "published_at": "2026-06-15T23:09:46", "published_display": "15 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio Inc. Q1 2026 Earnings: Pre\u2011Revenue Biotech Posts Wider\u2011Than\u2011Expected Loss, Stock Gains 5.47% - Positive Surprise Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxQeWRJclFKQmY1a3BKcmRKS3g2MkRVYkdVYzc0UWwwb3Q4dEYyVGhGOXpoQ1hHVnFNYUR2eVhFR3pSS0hUQ2V1dzN0SEhtQ0hjeUVKQzJ6dk5Ga0I0UDR0dlpGZW5SLWJQbkhTdlMtendLTjVjTE1lMG41YlhwX0FpY2JOcDVSbFl0MzdOTEI3X1JtcjNGdVBjODNkcThsU054eU5tQkowR2VldENodkQ3Z3RsUkExTC1kQWVrRXp0SlR6RUdncWpkSG05WnBEQlFGbF9seDk4NGRQb3VnY1dzYw?oc=5", "source_name": "B\u00f6l\u00fcm Sonu Canavar\u0131", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes", "summary": "Kyntra Bio announced new data from its Phase 3 MATTERHORN trial, demonstrating that roxadustat improves transfusion independence in patients with anemia stemming from lower-risk myelodysplastic syndromes (LR-MDS), irrespective of their ring sideroblast status. The findings highli", "url": "https://www.globenewswire.com/news-release/2026/06/11/3310789/0/en/Kyntra-Bio-Presents-New-Roxadustat-Data-on-Improvements-in-Transfusion-Independence-Regardless-of-Ring-Sideroblast-Status-in-Patients-with-Anemia-due-to-Lower-Risk-Myelodysplastic-.html", "source_name": "GlobeNewswire", "published_at": "2026-06-12T06:39:19", "published_display": "12 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio stock rises on roxadustat MDS trial data By Investing.com", "summary": "Kyntra Bio shares rose significantly after presenting data from a post hoc analysis of its Phase 3 MATTERHORN trial for roxadustat. The data showed that roxadustat improved transfusion independence in patients with lower-risk myelodysplastic syndromes and high transfusion burden.", "url": "https://za.investing.com/news/stock-market-news/kyntra-bio-stock-rises-on-roxadustat-mds-trial-data-93CH-4325008", "source_name": "Investing.com South Africa", "published_at": "2026-06-11T23:54:00", "published_display": "11 Jun 2026 23:54", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio Presents New Roxadustat Data On Improvements In Patients With Anemia Due To Lower-Risk Myelodysplastic Syndromes", "summary": "Kyntra Bio has unveiled new data regarding Roxadustat, showing its effectiveness in improving the condition of patients suffering from anemia due to lower-risk Myelodysplastic Syndromes. This information is released through Reuters and pertains to the company KYNB.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN42J0YU:0-kyntra-bio-presents-new-roxadustat-data-on-improvements-in-patients-with-anemia-due-to-lower-risk-myelodysplastic-syndromes/", "source_name": "TradingView", "published_at": "2026-06-11T20:09:58", "published_display": "11 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anemia MDS patients more often reached transfusion independence on roxadustat", "summary": "Kyntra Bio announced new post hoc Phase 3 MATTERHORN data for roxadustat, showing improved transfusion independence in patients with lower-risk myelodysplastic syndromes (LR-MDS) regardless of ring sideroblast status. Roxadustat achieved transfusion independence in 48% of patient", "url": "https://www.stocktitan.net/news/KYNB/kyntra-bio-presents-new-roxadustat-data-on-improvements-in-c7r6c7hzkinn.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:09:58", "published_display": "11 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio stock rises on roxadustat MDS trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNYXp2emZZUlF6UHpsOTA0ekYzMGpGU0dpT3BjTXBTRlJPSjlFbHZXb1VmTDg1T29zM3NEbE1PX0lYZ3IzMUNXTlozVlByYTd2Rm1ITG1XMWY3ZVpURXNyc0M0djFjOVpmUWp3djNyRUhxdW14UDhLLXphZmZKRklRd2c2dmpEV1MtT1hvUndtZ1YxeW1aVXhMTzR0ZWk5NjdZbzVJdmRaY2tJTWUya280TDF3dw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio Receives Final $4 Million Payment Under 2025 Share Purchase Deal With AstraZeneca", "summary": "Kyntra Bio announced it has received the final $4 million payment from AstraZeneca under a 2025 share purchase agreement. This payment concludes the deal, bringing the total funds received to $6 million. The agreement involved Kyntra Bio selling shares to AstraZeneca between 2023", "url": "https://www.moomoo.com/news/post/71328183/kyntra-bio-receives-final-4-million-payment-under-2025-share", "source_name": "Moomoo", "published_at": "2026-06-11T07:39:13", "published_display": "11 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio (NASDAQ: FGEN) completes $220M China sale payments", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNLUM5NDAwWmRUYlFEX3pHMGR4T2V6S0ZUZGgzQV96a3o1cDJvX1YtbXdKX29JRXNjZVBja0F4NDl1bl80NGdlN1ZUNm50bGE4ZjlmcUpGVGl1TElVZTRhbWJNM3haMWl3VDhNZkpBWUdIb2tiOUJWVHJCVHF2VXE1VUJVLXRIb1Y3N09zNGgyaXdjZFhhcWMzTzF0c21RS1UtZVQ3LWR3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Kyntra Bio Inc (KYNB) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic Advances ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kyntra-bio-inc-kynb-q1-070750643.html", "source_name": "GuruFocus.com", "published_at": "2026-05-12T07:07:50+00:00", "published_display": "12 May 2026 07:07", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kyntra-bio-q1-earnings-snapshot-202838709.html", "source_name": "Associated Press", "published_at": "2026-05-11T20:28:38+00:00", "published_display": "11 May 2026 20:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kyntra-bio-reports-first-quarter-200500671.html", "source_name": "GlobeNewswire", "published_at": "2026-05-11T20:05:00+00:00", "published_display": "11 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio (KYNB) Q1 2026 Earnings Transcript", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQZjVZZ1VqbGZnWVJiX2VfWXRaOWR4UG9iZFVvYlctSDkydXhxSHJJZmFaOWZjMEpmLTMzbDJLTHA4aGVuTGo3RktEUnAzSVRiLWx0cDRpY0dlWmotOGdZZzF0SjRNT0xlNFhSVGw5M2s1Q2szV3B6dE9fS1BMRkhSNkRoZE5rTmw0cUxhNkZ5c2xDOTRtUkdld2paaTRwQXROcXBWNQ?oc=5", "source_name": "The Motley Fool", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQd2V5REY1dm1LZXlNTGZOYl9JSEptN1p0NUJRdWEwZHpXSWxpRmIyRzZBbjBwSXhpMndKT0VmQW9nMU1NWkhTMnNLQWZIWlotM3JXbkp1MVRMTWVyVjN6N0tONGQxUUNhZ3A2Qk5vcUVXZ1g1VkVTODBEbDN5V213aENvZU9SR3loTVVYa1Vtd1BVcXlyVUVLSWVOZw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Kyntra Bio to Report First Quarter 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/kyntra-bio-report-first-quarter-200500915.html", "source_name": "GlobeNewswire", "published_at": "2026-05-04T20:05:00+00:00", "published_display": "04 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Kyntra Bio (KYNB) Upgraded to Buy: Here's What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNX1dhZ3lldWYzbkxYRnQ4SWFqWjQ4aEpHRjdhT2Etb2Zja0FkVFV4anhxcFZVSmhlM2NaVXF6MVF3Z0Z3c0o5REsyN2psNl9fLWxEODFJdUFXQjVYR2w1dnRrY3Y1RW80ZVVxR3c1bm1wUjdjYjNpY01zNWNWZURiTlVIeXZJR25QSU5RNUdYZFNIdDYyam1aNg?oc=5", "source_name": "Market source", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Kyntra Bio (KYNB) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE1QdEVETHJPNTNQZFRtMmVTanAtSzE5OU5HREx1ZTFsREktN1RtR0t5WUpWbTVLTXRXLUhVX05mVF96dHF2VzB2dFM2M0Q0SDRZZXQ5SVZaTGNrSnV0YzBqOWZzM0NQdw?oc=5", "source_name": "MarketBeat", "published_at": "2026-01-16T00:55:05+00:00", "published_display": "16 Jan 2026 00:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio (KYNB) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5vYmRSZnpMd3VTc1NTY1hWQ2dHcVBSSGNmSVdxcWZVV0g3cUpyQ0VSVzB3enZGUmFXSUh6NzRaRzkwRlBmTkJSQ2kwVGxNbmk4VUVLMFdBRnNrdw?oc=5", "source_name": "MarketBeat", "published_at": "2026-01-15T23:05:09+00:00", "published_display": "15 Jan 2026 23:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for Kyntra Bio Inc (KYNB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE9nNDladGNDbmk3RkFxNnIwOXItOFRpdWxIOHl4Z2x2SlZWYkxjOXltVnJRNE1oMms3NE9jMVhZYWtDbVJrdHVvZWdVVE9MVkppNkRwTXByNjNfQ2lOS05fMHREd1JvM0ZraU9INkpRaGF6SWNuc2tXMg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-01-10T07:13:41+00:00", "published_display": "10 Jan 2026 07:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOaE1PV3dpS25YWmwxd2pzVExNaGZkdkItdGNzdnlrY2VJaUVCSjd3ZF83TzMzTjFBQ2RwSXZhek5LUnBQbm5RUFprU1ctclIweUpRQ2o5SmNBU252dWgyX1BZNTJPV29UbWlZME11SVlFMUF0M3ZVUkVLWHVTRnpBM0t1VUxqRk1IRGc?oc=5", "source_name": "Market source", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FibroGen, Inc. has Changed its Name to Kyntra Bio, Inc", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPRUgtdVhEb0IxM3g4XzRmRFNuNlJXVnowTHR5cV9la05VVWpXMmlyWnh0R2lvOC02a2hQT083S25YeGpBT2hJUjhlTFJZbTF6UlZSckIteF8xQVFnckw4N3lYbEhZUkMzNlppTXNHbWRDc1VucEFOVUEzX09IQ0JpUm9iaU9IYVNjWHRxLVZMS0pSc2QyZ1o0YkdCenZ2ejVCMUNWZHpERQ?oc=5", "source_name": "marketscreener.com", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FibroGen rebrands as Kyntra Bio with new Nasdaq ticker KYNB", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNeW13RktBdi1fdE9wWTNkUTF4QjV5TFVsU3pQU0s1SGZzTl9PTXpqYjRlX0x6V1pnX3NjcFoyYVdqdlBUd1VpeXhEUmM4VEZKaUlLZXR1UnFvbHE5MGlyeWZrQ3gtcl9TS2ZGemRWSEFDemlnZ2lKeFN1NVFYUWdmWVBlTGZ4YXg3ZkFXdy1TU1B2emVnTklMVEw4UGtrUXNncWZhLTAtT3Y1RWlBTzNUUVNqSi0zYjA?oc=5", "source_name": "Investing.com", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FibroGen stock rises after announcing rebrand to Kyntra Bio", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNcDR1VnQzdlRCX0dNaHR6cVVfdFh3YXFnSE1EMHVJMXo1b256dW1Tb1pNLWlCS2xGVkhKbUkxaU55N1ctWGdvUlhZUVp4QnBLZjF6MGVKdHdKakJBamN4M1l4NmRGVEwwZ3poaXZ5RjdPdUxiaVRyVHpNRTBENmcxYjdZZ1hvamljU25UVGNvZjlCZnctVGRXNWpncGpweVlYXzh4VkFPNWhvUjBwMTUyM3dkR21LcmNNUkZUOGl3?oc=5", "source_name": "Investing.com", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Kyntra Bio Inc. (KYNB) Sheds 1.5% as Shares Test Key Support Zone - Counter Trend Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPYm5XZ3ZpbUMya2RBVFVHdnJCWlRaaXpSZUxQaTVUdGRKbTZ6WWh1RVlNbVV6a1BPQjVid052OUZSZDFVMFZqZlhzcU93OTZhcHZSdVA4Vi14Qm9PN1hTWEtwbGJzbDBvTWZWZURuQTllTUh2UTJQV3g2UFZXMmd5TmZ3RTMybGpvaHNNM2FnbkYtUFdyMm9RWWhfWlN1b1FITUVpN0RyWQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-16T00:36:24+00:00", "published_display": "16 Jul 2026 00:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in KYNTRA BIO INC (KYNB)", "summary": "This article analyzes the hypothetical returns of investing $1,000 in KYNTRA BIO INC (KYNB). It reveals that an investment made a year ago would currently be worth $788, representing a 21% decrease. The article also provides an overview of Kyntra Bio, Inc.'s business, focusing on", "url": "https://www.stocktitan.net/tools/stock-return-calculator/KYNB", "source_name": "Stock Titan", "published_at": "2026-07-09T01:41:00", "published_display": "09 Jul 2026 01:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Initiates Kyntra Bio(KYNB.US) With Buy Rating, Announces Target Price $35", "summary": "Oppenheimer has initiated coverage on Kyntra Bio (KYNB.US) with a \"Buy\" rating. The firm also announced a target price of $35 for the company's shares. This indicates a positive outlook from Oppenheimer on Kyntra Bio's future performance.", "url": "https://www.moomoo.com/t/news/post/72539511/yNeMIv6Ynb?futusource=nnq_personal_guest", "source_name": "Moomoo", "published_at": "2026-07-08T05:41:00", "published_display": "08 Jul 2026 05:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Maintains Kyntra Bio(KYNB.US) With Buy Rating, Maintains Target Price $35", "summary": "Oppenheimer has reiterated its Buy rating for Kyntra Bio (KYNB.US), maintaining a target price of $35. This indicates continued confidence from the firm in the biotechnology company's performance and future prospects.", "url": "https://www.moomoo.com/news/post/72586860/oppenheimer-maintains-kyntra-bio-kynbus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-07-07T21:10:59", "published_display": "07 Jul 2026 21:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer initiates Kyntra Bio stock coverage with outperform rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQV0VfQjZVbVRrdTJyYm1FbDRPWFFpbFktTGxYb2hnanowMW1zS1o1N0QwY24yNXdkREZLWG5zR3FHOXVTbV85MHM0UWpsSXNfcDZJSHZSRE5Xa2NEeS1LSk92cm9VNFlFbTFxOVNyell3bENmSm95UktjRlZFeVozOUlHS1ktM2dqZE05dW02TDl4cTBaUkM0ZXlLbjI2UHBtalpTYl9zV2piejJ3aU1MM04yZ0kwZk5UNlFia3VUSDdMVk5FZVhNN2xn?oc=5", "source_name": "Investing.com", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Net margin % of Kyntra Bio, Inc. \u2013 DUS:1FG0", "summary": "This article provides access to the net margin percentage for Kyntra Bio, Inc. (DUS:1FG0) on the TradingView platform. It is a financial data point for the company listed on the Dusseldorf Stock Exchange. The content primarily focuses on the display of this financial metric withi", "url": "https://www.tradingview.com/symbols/DUS-1FG0/financials-statistics-and-ratios/net-margin/", "source_name": "TradingView", "published_at": "2026-07-05T08:41:36", "published_display": "05 Jul 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Kyntra Bio, Inc. \u2013 DUS:1FG0", "summary": "This article provides the forward price-to-sales ratio for Kyntra Bio, Inc. (DUS:1FG0) on the Dusseldorf Stock Exchange. It indicates no current trading data and emphasizes that the content focuses on financial metrics for this specific pharmaceutical stock.", "url": "https://www.tradingview.com/symbols/DUS-1FG0/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T17:39:50", "published_display": "03 Jul 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Kyntra Bio, Inc. \u2013 DUS:1FG0", "summary": "The article presents the enterprise value to revenue forward for Kyntra Bio, Inc. (DUS:1FG0) on the Dusseldorf Stock Exchange. It indicates that the market was closed with no trades recorded for the period. The content is primarily a financial snapshot on TradingView, noting the ", "url": "https://www.tradingview.com/symbols/DUS-1FG0/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T23:41:26", "published_display": "29 Jun 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Kyntra Bio, Inc. \u2013 NASDAQ:KYNB", "summary": "This article provides access to the \"Price to book forward\" financial data for Kyntra Bio, Inc. (NASDAQ: KYNB) on the TradingView platform. It highlights that the market is currently closed and no trades have occurred for the stock. The content primarily focuses on navigation and", "url": "https://www.tradingview.com/symbols/NASDAQ-KYNB/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T14:11:10", "published_display": "26 Jun 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KYNB Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Kyntra Bio, Inc. (KYNB) stock for 2027, based on analyst ratings. It details the company's current stock price, historical performance, volatility, market capitalization, and upcoming earnings report. The piece also includes f", "url": "https://www.tradingview.com/symbols/NASDAQ-KYNB/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T12:38:58", "published_display": "26 Jun 2026 12:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio, Inc. Actuals & Estimates (NASDAQ:KYNB)", "summary": "Kyntra Bio, Inc. (NASDAQ:KYNB) stock is currently trading at $7.24, showing a 1.73% increase in the past 24 hours. Analysts' future price estimates range from $30.00 to $43.00. The company's last reported earnings were -$3.76 per share, missing the estimate, with revenue at $3.70", "url": "https://www.tradingview.com/symbols/NASDAQ-KYNB/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:11:10", "published_display": "26 Jun 2026 07:11", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Kyntra Bio, Inc. \u2013 NASDAQ:KYNB", "summary": "The article focuses on the enterprise value to EBIT forward of Kyntra Bio, Inc. (NASDAQ: KYNB). It provides a snapshot of the company's financial overview within the TradingView platform, detailing market data and analytical tools available for investors. The content appears to b", "url": "https://www.tradingview.com/symbols/NASDAQ-KYNB/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T04:10:21", "published_display": "26 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Kyntra Bio, Inc. \u2013 TRADEGATE:1FG0", "summary": "This article provides the \"Price to book forward\" for Kyntra Bio, Inc. (TRADEGATE:1FG0) and indicates that the market is currently closed with no trades. It is a financial data point presented on the TradingView platform.", "url": "https://www.tradingview.com/symbols/TRADEGATE-1FG0/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T02:10:21", "published_display": "26 Jun 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio Inc. (KYNB) Edges Higher on Above-Average Volume, Tests Key Resistance Zone - ETH Profile", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOWEpNampFU1AtclpaRWJLWVBNQ0FsZEZoZEwzc05SZEVIZzgwdkJmN1V4YUpqcmtnZnNTY0RzUWVIYUdZaUJWTlF6ZHRPRXdib0hqZHRyWG9YWk9HQlJScFpTU1dFWG1aZHlKQUtRRzRsNW5YdG5uNVNPcmNVZ0FkRk8xQTVCUlp1RU5VUVpzb1BncGlKUkJyaHZlQk4yYWRCX0dZVzV3akJ0ZzUtblBsTkJpc3VUOUpvdERQRQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: EPS Miss Reflects Continued R&D Investment - CEO Earnings Statement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNZmM3WnJSeU9fOTRLQmRHRjJrYV9YREZXRUgwOXBvbVA2QVhONzRUV19QVklIT3dwOUxNNFltWDEyeXpCYUZJQWNYV1JoMU1zS0RjNHBiVmRRQ05wYWFVTnJha3BQd1lfNXVSRlg1cUlxOGxiaFp5aVBLV2t1R2xvSVI2SHdxYi1MdkNNN21BR0VId2JaTVRVUkZMWUt5NDc1Q25VejZEUTNBdlVod1AxQkpTZnBTRHo4Wk96d21VSXc?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Net debt of Kyntra Bio, Inc. \u2013 DUS:1FG0", "summary": "The article focuses on the net debt of Kyntra Bio, Inc. (DUS:1FG0), traded on the Dusseldorf Stock Exchange. It indicates that the market is currently closed with no trades recorded. The content seems to be a financial data page from TradingView, providing an overview of Kyntra B", "url": "https://www.tradingview.com/symbols/DUS-1FG0/financials-balance-sheet/net-debt/", "source_name": "TradingView", "published_at": "2026-06-19T10:40:56", "published_display": "19 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KYNTRA BIO (KYNB) director Ho Maykin awarded 7,000 stock options at $7.13", "summary": "KYNTRA BIO (KYNB) director Ho Maykin was granted 7,000 stock options, which allows him to purchase common stock at an exercise price of $7.13 per share. These options are part of a compensation award and will vest in four equal quarterly installments from the grant date, expiring", "url": "https://www.stocktitan.net/sec-filings/KYNB/form-4-kyntra-bio-inc-insider-trading-activity-1a6eb7da391e.html", "source_name": "Stock Titan", "published_at": "2026-06-19T03:10:13", "published_display": "19 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings ratio of Kyntra Bio, Inc. \u2013 DUS:1FG0", "summary": "This article displays the price to earnings ratio for Kyntra Bio, Inc. (DUS:1FG0) on the TradingView platform. The content is primarily a data point regarding the company's financials on the Dusseldorf Stock Exchange, indicating \"No trades\" at the time of viewing.", "url": "https://www.tradingview.com/symbols/DUS-1FG0/financials-statistics-and-ratios/price-earnings/", "source_name": "TradingView", "published_at": "2026-06-18T21:40:56", "published_display": "18 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio, Inc. Statistics \u2013 DUS:1FG0", "summary": "This page provides detailed financial statistics and ratios for Kyntra Bio, Inc. (DUS:1FG0) listed on the Dusseldorf Stock Exchange. Users can find annual and quarterly data for various metrics, including valuation, profitability, liquidity, solvency ratios, and per-share metrics", "url": "https://www.tradingview.com/symbols/DUS-1FG0/financials-statistics-and-ratios/", "source_name": "TradingView", "published_at": "2026-06-18T19:09:08", "published_display": "18 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Basic earnings per share (basic EPS) of Kyntra Bio, Inc. \u2013 DUS:1FG0", "summary": "This article presents the basic earnings per share (basic EPS) for Kyntra Bio, Inc., traded under the symbol DUS:1FG0 on the Dusseldorf Stock Exchange. It includes period values, changes, and change percentages for this financial metric. The data is provided by ICE Data Services ", "url": "https://www.tradingview.com/symbols/DUS-1FG0/financials-income-statement/earnings-per-share-basic/", "source_name": "TradingView", "published_at": "2026-06-18T18:09:08", "published_display": "18 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio (KYNB) director receives 7,000 options at $7.13 strike", "summary": "Kyntra Bio director Jeffrey L. Edwards was granted 7,000 stock options with an exercise price of $7.13 per share. These options serve as compensation, vesting in four equal quarterly installments, and expire on June 11, 2036. This grant aligns Edwards' equity incentives with the ", "url": "https://www.stocktitan.net/sec-filings/KYNB/form-4-kyntra-bio-inc-insider-trading-activity-5aabfba2d1f7.html", "source_name": "Stock Titan", "published_at": "2026-06-17T23:40:46", "published_display": "17 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio (KYNB) awards 7,000 stock options to director", "summary": "Kyntra Bio Inc. (KYNB) has awarded its director, James A. Schoeneck, 7,000 stock options with an exercise price of $7.13 per share and an expiration date of June 11, 2036. The options will vest in four equal quarterly installments commencing from the grant date of June 12, 2026. ", "url": "https://www.stocktitan.net/sec-filings/KYNB/form-4-kyntra-bio-inc-insider-trading-activity-3ff354a01d74.html", "source_name": "Stock Titan", "published_at": "2026-06-17T23:40:46", "published_display": "17 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KYNTRA BIO (KYNB) director awarded 7,000 stock options at $7.13 strike", "summary": "KYNTRA BIO director Michael Kauffman was granted 7,000 stock options with an exercise price of $7.13 per share and an expiration date of June 11, 2036. The options will vest in four equal quarterly installments from the grant date. This transaction, reported via a Form 4 SEC fili", "url": "https://www.stocktitan.net/sec-filings/KYNB/form-4-kyntra-bio-inc-insider-trading-activity-12e0c1250fa2.html", "source_name": "Stock Titan", "published_at": "2026-06-17T23:40:46", "published_display": "17 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio shareholders elect director and approve executive pay at annual meeting", "summary": "At its 2026 annual meeting, Kyntra Bio shareholders elected Michael Kauffman, M.D., Ph.D., as a Class III director and approved the compensation for the company's named executive officers on an advisory basis. They also ratified PricewaterhouseCoopers LLP as the independent regis", "url": "https://www.investing.com/news/sec-filings/kyntra-bio-shareholders-elect-director-and-approve-executive-pay-at-annual-meeting-93CH-4744179", "source_name": "Investing.com", "published_at": "2026-06-17T09:10:30", "published_display": "17 Jun 2026 09:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio (NASDAQ: KYNB) investors back board, pay and PwC auditor", "summary": "Kyntra Bio (NASDAQ: KYNB) shareholders approved key proposals at their 2026 annual meeting, including the election of Michael Kauffman as a Class III director, advisory approval of executive compensation, and the ratification of PricewaterhouseCoopers LLP as the independent regis", "url": "https://www.stocktitan.net/sec-filings/KYNB/8-k-kyntra-bio-inc-reports-material-event-958a04699a80.html", "source_name": "Stock Titan", "published_at": "2026-06-15T23:09:46", "published_display": "15 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio Inc. Q1 2026 Earnings: Pre\u2011Revenue Biotech Posts Wider\u2011Than\u2011Expected Loss, Stock Gains 5.47% - Positive Surprise Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxQeWRJclFKQmY1a3BKcmRKS3g2MkRVYkdVYzc0UWwwb3Q4dEYyVGhGOXpoQ1hHVnFNYUR2eVhFR3pSS0hUQ2V1dzN0SEhtQ0hjeUVKQzJ6dk5Ga0I0UDR0dlpGZW5SLWJQbkhTdlMtendLTjVjTE1lMG41YlhwX0FpY2JOcDVSbFl0MzdOTEI3X1JtcjNGdVBjODNkcThsU054eU5tQkowR2VldENodkQ3Z3RsUkExTC1kQWVrRXp0SlR6RUdncWpkSG05WnBEQlFGbF9seDk4NGRQb3VnY1dzYw?oc=5", "source_name": "B\u00f6l\u00fcm Sonu Canavar\u0131", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes", "summary": "Kyntra Bio announced new data from its Phase 3 MATTERHORN trial, demonstrating that roxadustat improves transfusion independence in patients with anemia stemming from lower-risk myelodysplastic syndromes (LR-MDS), irrespective of their ring sideroblast status. The findings highli", "url": "https://www.globenewswire.com/news-release/2026/06/11/3310789/0/en/Kyntra-Bio-Presents-New-Roxadustat-Data-on-Improvements-in-Transfusion-Independence-Regardless-of-Ring-Sideroblast-Status-in-Patients-with-Anemia-due-to-Lower-Risk-Myelodysplastic-.html", "source_name": "GlobeNewswire", "published_at": "2026-06-12T06:39:19", "published_display": "12 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio stock rises on roxadustat MDS trial data By Investing.com", "summary": "Kyntra Bio shares rose significantly after presenting data from a post hoc analysis of its Phase 3 MATTERHORN trial for roxadustat. The data showed that roxadustat improved transfusion independence in patients with lower-risk myelodysplastic syndromes and high transfusion burden.", "url": "https://za.investing.com/news/stock-market-news/kyntra-bio-stock-rises-on-roxadustat-mds-trial-data-93CH-4325008", "source_name": "Investing.com South Africa", "published_at": "2026-06-11T23:54:00", "published_display": "11 Jun 2026 23:54", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio Presents New Roxadustat Data On Improvements In Patients With Anemia Due To Lower-Risk Myelodysplastic Syndromes", "summary": "Kyntra Bio has unveiled new data regarding Roxadustat, showing its effectiveness in improving the condition of patients suffering from anemia due to lower-risk Myelodysplastic Syndromes. This information is released through Reuters and pertains to the company KYNB.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN42J0YU:0-kyntra-bio-presents-new-roxadustat-data-on-improvements-in-patients-with-anemia-due-to-lower-risk-myelodysplastic-syndromes/", "source_name": "TradingView", "published_at": "2026-06-11T20:09:58", "published_display": "11 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anemia MDS patients more often reached transfusion independence on roxadustat", "summary": "Kyntra Bio announced new post hoc Phase 3 MATTERHORN data for roxadustat, showing improved transfusion independence in patients with lower-risk myelodysplastic syndromes (LR-MDS) regardless of ring sideroblast status. Roxadustat achieved transfusion independence in 48% of patient", "url": "https://www.stocktitan.net/news/KYNB/kyntra-bio-presents-new-roxadustat-data-on-improvements-in-c7r6c7hzkinn.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:09:58", "published_display": "11 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio stock rises on roxadustat MDS trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNYXp2emZZUlF6UHpsOTA0ekYzMGpGU0dpT3BjTXBTRlJPSjlFbHZXb1VmTDg1T29zM3NEbE1PX0lYZ3IzMUNXTlozVlByYTd2Rm1ITG1XMWY3ZVpURXNyc0M0djFjOVpmUWp3djNyRUhxdW14UDhLLXphZmZKRklRd2c2dmpEV1MtT1hvUndtZ1YxeW1aVXhMTzR0ZWk5NjdZbzVJdmRaY2tJTWUya280TDF3dw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio Receives Final $4 Million Payment Under 2025 Share Purchase Deal With AstraZeneca", "summary": "Kyntra Bio announced it has received the final $4 million payment from AstraZeneca under a 2025 share purchase agreement. This payment concludes the deal, bringing the total funds received to $6 million. The agreement involved Kyntra Bio selling shares to AstraZeneca between 2023", "url": "https://www.moomoo.com/news/post/71328183/kyntra-bio-receives-final-4-million-payment-under-2025-share", "source_name": "Moomoo", "published_at": "2026-06-11T07:39:13", "published_display": "11 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio (NASDAQ: FGEN) completes $220M China sale payments", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNLUM5NDAwWmRUYlFEX3pHMGR4T2V6S0ZUZGgzQV96a3o1cDJvX1YtbXdKX29JRXNjZVBja0F4NDl1bl80NGdlN1ZUNm50bGE4ZjlmcUpGVGl1TElVZTRhbWJNM3haMWl3VDhNZkpBWUdIb2tiOUJWVHJCVHF2VXE1VUJVLXRIb1Y3N09zNGgyaXdjZFhhcWMzTzF0c21RS1UtZVQ3LWR3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio Inc (KYNB) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic Advances ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kyntra-bio-inc-kynb-q1-070750643.html", "source_name": "GuruFocus.com", "published_at": "2026-05-12T07:07:50+00:00", "published_display": "12 May 2026 07:07", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kyntra-bio-q1-earnings-snapshot-202838709.html", "source_name": "Associated Press", "published_at": "2026-05-11T20:28:38+00:00", "published_display": "11 May 2026 20:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kyntra-bio-reports-first-quarter-200500671.html", "source_name": "GlobeNewswire", "published_at": "2026-05-11T20:05:00+00:00", "published_display": "11 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio (KYNB) Q1 2026 Earnings Transcript", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQZjVZZ1VqbGZnWVJiX2VfWXRaOWR4UG9iZFVvYlctSDkydXhxSHJJZmFaOWZjMEpmLTMzbDJLTHA4aGVuTGo3RktEUnAzSVRiLWx0cDRpY0dlWmotOGdZZzF0SjRNT0xlNFhSVGw5M2s1Q2szV3B6dE9fS1BMRkhSNkRoZE5rTmw0cUxhNkZ5c2xDOTRtUkdld2paaTRwQXROcXBWNQ?oc=5", "source_name": "The Motley Fool", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQd2V5REY1dm1LZXlNTGZOYl9JSEptN1p0NUJRdWEwZHpXSWxpRmIyRzZBbjBwSXhpMndKT0VmQW9nMU1NWkhTMnNLQWZIWlotM3JXbkp1MVRMTWVyVjN6N0tONGQxUUNhZ3A2Qk5vcUVXZ1g1VkVTODBEbDN5V213aENvZU9SR3loTVVYa1Vtd1BVcXlyVUVLSWVOZw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio to Report First Quarter 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/kyntra-bio-report-first-quarter-200500915.html", "source_name": "GlobeNewswire", "published_at": "2026-05-04T20:05:00+00:00", "published_display": "04 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio (KYNB) Upgraded to Buy: Here's What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNX1dhZ3lldWYzbkxYRnQ4SWFqWjQ4aEpHRjdhT2Etb2Zja0FkVFV4anhxcFZVSmhlM2NaVXF6MVF3Z0Z3c0o5REsyN2psNl9fLWxEODFJdUFXQjVYR2w1dnRrY3Y1RW80ZVVxR3c1bm1wUjdjYjNpY01zNWNWZURiTlVIeXZJR25QSU5RNUdYZFNIdDYyam1aNg?oc=5", "source_name": "Market source", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio (KYNB) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE1QdEVETHJPNTNQZFRtMmVTanAtSzE5OU5HREx1ZTFsREktN1RtR0t5WUpWbTVLTXRXLUhVX05mVF96dHF2VzB2dFM2M0Q0SDRZZXQ5SVZaTGNrSnV0YzBqOWZzM0NQdw?oc=5", "source_name": "MarketBeat", "published_at": "2026-01-16T00:55:05+00:00", "published_display": "16 Jan 2026 00:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyntra Bio (KYNB) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5vYmRSZnpMd3VTc1NTY1hWQ2dHcVBSSGNmSVdxcWZVV0g3cUpyQ0VSVzB3enZGUmFXSUh6NzRaRzkwRlBmTkJSQ2kwVGxNbmk4VUVLMFdBRnNrdw?oc=5", "source_name": "MarketBeat", "published_at": "2026-01-15T23:05:09+00:00", "published_display": "15 Jan 2026 23:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for Kyntra Bio Inc (KYNB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE9nNDladGNDbmk3RkFxNnIwOXItOFRpdWxIOHl4Z2x2SlZWYkxjOXltVnJRNE1oMms3NE9jMVhZYWtDbVJrdHVvZWdVVE9MVkppNkRwTXByNjNfQ2lOS05fMHREd1JvM0ZraU9INkpRaGF6SWNuc2tXMg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-01-10T07:13:41+00:00", "published_display": "10 Jan 2026 07:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOaE1PV3dpS25YWmwxd2pzVExNaGZkdkItdGNzdnlrY2VJaUVCSjd3ZF83TzMzTjFBQ2RwSXZhek5LUnBQbm5RUFprU1ctclIweUpRQ2o5SmNBU252dWgyX1BZNTJPV29UbWlZME11SVlFMUF0M3ZVUkVLWHVTRnpBM0t1VUxqRk1IRGc?oc=5", "source_name": "Market source", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FibroGen, Inc. has Changed its Name to Kyntra Bio, Inc", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPRUgtdVhEb0IxM3g4XzRmRFNuNlJXVnowTHR5cV9la05VVWpXMmlyWnh0R2lvOC02a2hQT083S25YeGpBT2hJUjhlTFJZbTF6UlZSckIteF8xQVFnckw4N3lYbEhZUkMzNlppTXNHbWRDc1VucEFOVUEzX09IQ0JpUm9iaU9IYVNjWHRxLVZMS0pSc2QyZ1o0YkdCenZ2ejVCMUNWZHpERQ?oc=5", "source_name": "marketscreener.com", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FibroGen rebrands as Kyntra Bio with new Nasdaq ticker KYNB", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNeW13RktBdi1fdE9wWTNkUTF4QjV5TFVsU3pQU0s1SGZzTl9PTXpqYjRlX0x6V1pnX3NjcFoyYVdqdlBUd1VpeXhEUmM4VEZKaUlLZXR1UnFvbHE5MGlyeWZrQ3gtcl9TS2ZGemRWSEFDemlnZ2lKeFN1NVFYUWdmWVBlTGZ4YXg3ZkFXdy1TU1B2emVnTklMVEw4UGtrUXNncWZhLTAtT3Y1RWlBTzNUUVNqSi0zYjA?oc=5", "source_name": "Investing.com", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FibroGen stock rises after announcing rebrand to Kyntra Bio", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNcDR1VnQzdlRCX0dNaHR6cVVfdFh3YXFnSE1EMHVJMXo1b256dW1Tb1pNLWlCS2xGVkhKbUkxaU55N1ctWGdvUlhZUVp4QnBLZjF6MGVKdHdKakJBamN4M1l4NmRGVEwwZ3poaXZ5RjdPdUxiaVRyVHpNRTBENmcxYjdZZ1hvamljU25UVGNvZjlCZnctVGRXNWpncGpweVlYXzh4VkFPNWhvUjBwMTUyM3dkR21LcmNNUkZUOGl3?oc=5", "source_name": "Investing.com", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 92, "total_relevant": 56, "sentiment_summary": {"positive": 13, "negative": 4, "neutral": 39, "score": 54, "total": 56, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 75, "events": [{"event": "general", "label": "Market update", "weight": 12.65, "count": 23}, {"event": "earnings", "label": "Earnings", "weight": 11.21, "count": 22}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "guidance", "label": "Guidance", "weight": 1.45, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 13, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 7.23, "latest_week": "2026-07-17", "one_week_move": -4.9, "four_week_move": 7.9, "twelve_week_move": 1.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.055852, "market_dynamics_buy_signal": false, "relative_strength": -24.906124, "fair_value_gap": -54.6, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 48.91, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.9% over one week, +7.9% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 14}, {"label": "Market source", "count": 9}, {"label": "Stock Titan", "count": 8}, {"label": "Investing.com", "count": 5}, {"label": "dars.gov.et", "count": 3}, {"label": "Moomoo", "count": 3}, {"label": "GlobeNewswire", "count": 3}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 47}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 23}, {"label": "Earnings", "count": 22}, {"label": "Analyst action", "count": 5}, {"label": "Balance sheet", "count": 2}, {"label": "Guidance", "count": 2}, {"label": "Regulatory and legal", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "47", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-4.9% over one week, +7.9% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Kyntra Bio Inc. (KYNB) Sheds 1.5% as Shares Test Key Support Zone - Counter Trend Trade"}], "updated_at": "2026-07-22T03:49:03.527092+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}